Protagonist Therapeutics (PTGX) Shares Outstanding (Diluted Average) (2022 - 2026)

Protagonist Therapeutics has disclosed Shares Outstanding (Diluted Average) across 5 years of filings, most recently posting $70.5 million for Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $70.5 million, up 11.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $70.5 million (up 11.96% YoY), and the FY2025 annual result was $63.6 million, down 2.31% from the prior year.
• Shares Outstanding (Diluted Average) came in at $70.5 million for Q1 2026 at Protagonist Therapeutics, up from $63.6 million in the prior quarter.
• In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $70.5 million in Q1 2026 to a low of $48.8 million in Q1 2022.
• The 5-year median for Shares Outstanding (Diluted Average) is $61.5 million (2024), against an average of $58.9 million.
• Across the five-year window, Shares Outstanding (Diluted Average) advanced 25.75% in 2024 and slipped 2.31% in 2025, its largest moves.
• Protagonist Therapeutics' Shares Outstanding (Diluted Average) stood at $49.1 million in 2022, then gained by 15.59% to $56.8 million in 2023, then advanced by 14.65% to $65.1 million in 2024, then fell by 2.31% to $63.6 million in 2025, then rose by 10.88% to $70.5 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $70.5 million (Q1 2026), $63.6 million (Q4 2025), and $63.8 million (Q3 2025), per Business Quant data.